Incorporating patient preferences into drug development and regulatory decision making: Results from a quantitative pilot study with cancer patients, carers, and regulators.

Postmus, D; Mavris, M; Hillege, H L; Salmonson, T; Ryll, B; Plate, A; Moulon, I; Eichler, H-G; Bere, N; Pignatti, F

Postmus, D; Mavris, M; Hillege, H L; Salmonson, T; Ryll, B; Plate, A; Moulon, I; Eichler, H-G; Bere, N; Pignatti, F.

Affiliation

Postmus D; European Medicines Agency, London, UK.
Mavris M; University of Groningen, University Medical Center Groningen, The Netherlands.
Hillege HL; European Medicines Agency, London, UK.
Salmonson T; University of Groningen, University Medical Center Groningen, The Netherlands.
Ryll B; European Medicines Agency, London, UK.
Plate A; Läkemedelsverket Medical Products Agency, Uppsala, Sweden.
Moulon I; Melanoma Patient Network Europe.
Eichler HG; Myeloma Patients Europe.
Bere N; European Medicines Agency, London, UK.
Pignatti F; European Medicines Agency, London, UK.

Clin Pharmacol Ther ; 99(5): 548-54, 2016 May.

Article in En | MEDLINE | ID: mdl-26715217

Subject(s)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Drug Design / Decision Making / Drug and Narcotic Control / Patient Preference / Neoplasms Type of study: Prognostic_studies / Qualitative_research Aspects: Patient_preference Limits: Humans Language: En Journal: Clin Pharmacol Ther Year: 2016 Document type: Article Affiliation country: Reino Unido

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google